OncoGenex Pharmaceuticals Inc. (Nasdaq:OXGI) will receive BIOTECanada's Gold Leaf Award for biotech company of the year, it announced Thursday.
The cancer treatment developer, which is headquartered in Washington with an office in Vancouver, said the award recognizes strong overall performance, leadership and achievement in the industry, and would be presented on May 4 at the BIO 2010 International Convention in Chicago.
"2009 was a tremendous year for OncoGenex, and we are honored to be recognized with this esteemed award," said Scott Cormack, the company's president and CEO.
In December, the company formed a partnership with Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) to develop and commercialize its lead drug candidate OGX-011, which would be used to enhance the effects of therapy treatments in non-small cell lung and breast cancer.
BIOTECanada is a national industry-funded association with more than 250 member companies.
OncoGenex's share price range during the past week: $20.54 and $20.57; 52-week high: $42.99; 52-week low: $3.95.